Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BUDA vs EXOZ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BUDA Captures Overall Composite Edge (34.2 SELL vs 42.3 HOLD), While EXOZ Leads 3–1 on Growth & Valuation Pillars

BUDA Overall Winner 6-Pillar Tally: BUDA 1 – 3 EXOZ (2 Tie) Matrix Metrics: BUDA 1 – 6 EXOZ

As of Nov 20, 2026, BUDA (BUDA) captures the overall head-to-head institutional edge over eXoZymes Inc. (EXOZ) on higher Unified Composite conviction (34.2/100 SELL vs. 42.3/100 HOLD) after splitting the core matrix 1–6 (led by Options & Positioning), while EXOZ wins 3–1 across the 6-pillar growth and valuation breakdown. BUDA trades at $5.30 (N/M Forward P/E, N/A operating margin) versus EXOZ at $2.90 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EXOZ currently prints a higher short-term Unified Composite Score (42.3/100 HOLD vs. BUDA 34.2/100 SELL), BUDA captures the overall institutional head-to-head verdict (1–6 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY).
  • Technical & Structure Timing Caution: BUDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.2); meanwhile EXOZ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BUDA vs EXOZ
BUDA US Equity Head-to-Head Winner
BUDA
Institutional Equity
$5.30
-0.19% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.03β · 71% Vol
Unified Composite Score
34.2 / 100 SELL
Tech 35.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 28
RSI-14: 28.2 · SMA20: $6.51 · SMA50: $7.15
EXOZ NASDAQ
eXoZymes Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.90
-14.05% 1D
Market Cap $31.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.86β · 109% Vol
Unified Composite Score
42.3 / 100 HOLD
Tech 25.0 Fund 51.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $3.96 · SMA50: $4.82

6-Pillar Scorecard Institutional Category Breakdown (BUDA 1 – 3 EXOZ)

Columns: Metric · BUDA · EXOZ
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale EXOZ
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $31.9M
3. Profitability & Quality EXOZ
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -187.2%
4. Balance Sheet & Cash Flow EXOZ
Cash Generation (TTM) N/A -$7.1M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $4.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BUDA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BUDA (1) vs EXOZ (6)
Institutional Metric BUDA EXOZ Criterion Row Edge
Market Capitalization
Scale
N/A $31.9M Larger Scale EXOZ
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth EXOZ
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin EXOZ
Net Profit Margin
Profitability
N/A 0.0% Higher Margin EXOZ
Return on Equity (ROE)
Capital Efficiency
N/A -187.2% Higher ROE EXOZ
52-Week Range Position
Momentum
1% ($5–$12) 1% ($3–$17) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
-0.03β · 71% Vol 0.86β · 109% Vol Lower Realized Risk BUDA
Unified Institutional Score
Composite Signal
34.2 / 100 (SELL) 42.3 / 100 (HOLD) Higher Composite EXOZ
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$7.1M ($4.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BUDA +4.61 pp
BUDA: -20.9% · EXOZ: -25.51%
3M Horizon BUDA +17.41 pp
BUDA: -41.33% · EXOZ: -58.74%
6M Horizon BUDA +31.09 pp
BUDA: -38.01% · EXOZ: -69.1%
1Y Horizon BUDA +35.34 pp
BUDA: -34.65% · EXOZ: -69.99%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BUDA vs EXOZ. Trailing 12-month operating profitability (BUDA N/A vs EXOZ 0.0%) and valuation multiples (BUDA N/M vs EXOZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BUDA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
EXOZ ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-187.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BUDA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BUDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EXOZ BREAKDOWN
57d in phase · OBV DISTRIBUTION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact EXOZ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BUDA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EXOZ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $31.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BUDA vs EXOZ Key Questions & Quantitative Answers

As of Nov 20, 2026, BUDA (BUDA) captures the overall head-to-head institutional edge over eXoZymes Inc. (EXOZ) on higher Unified Composite conviction (34.2/100 SELL vs. 42.3/100 HOLD) after splitting the core matrix 1–6 (led by Options & Positioning), while EXOZ wins 3–1 across the 6-pillar growth and valuation breakdown. BUDA trades at $5.30 (N/M Forward P/E, N/A operating margin) versus EXOZ at $2.90 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EXOZ currently prints a higher short-term Unified Composite Score (42.3/100 HOLD vs. BUDA 34.2/100 SELL), BUDA captures the overall institutional head-to-head verdict (1–6 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY). Technical & Structure Timing Caution: BUDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.2); meanwhile EXOZ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EXOZ leads the Growth & Scale pillar: BUDA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with EXOZ at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BUDA generates N/A in USD-normalized revenue versus N/A for EXOZ. In operating R&D and SG&A reinvestment, BUDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EXOZ.

BUDA and EXOZ trade at balanced relative valuation multiples. BUDA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EXOZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BUDA (N/A ROE) versus EXOZ (-187.2% ROE) capital efficiency.

In options market volatility and institutional positioning, BUDA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.03β · 71% Vol realized risk). By comparison, EXOZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.86β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.